CCMU
MLTX icon

Cheyne Capital Management (UK)’s MoonLake Immunotherapeutics MLTX Stock Holding History

Cheyne Capital Management (UK)’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-32,129
Closed -$337K – 38
2022
Q4 		$337K Buy
+32,129
New +$286K 0.59% 45

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Cheyne Capital Management (UK)'s MLTX Position: Q1 2023 in Review

Cheyne Capital Management (UK) sold out of MoonLake Immunotherapeutics (MLTX) in Q1 2023, closing a stake of 32,129 shares — an estimated $337K sold.

Cheyne Capital Management (UK) first reported a position in MLTX in Q4 2022 and held it in 1 quarter. The position peaked at $337K in Q4 2022. 43 funds tracked by Wall St. Rank hold MLTX as of Q1 2023.

  • Cheyne Capital Management (UK) reported no remaining MoonLake Immunotherapeutics position as of Q1 2023 after selling out during the quarter.
  • Cheyne Capital Management (UK) sold 32,129 MoonLake Immunotherapeutics shares in Q1 2023, an estimated $337K.
  • Cheyne Capital Management (UK) first reported a position in MoonLake Immunotherapeutics in Q4 2022 and held it in 1 quarter.
  • Cheyne Capital Management (UK)'s MoonLake Immunotherapeutics position peaked at $337K in Q4 2022.
  • 43 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2023.

Based on Cheyne Capital Management (UK)'s 13F filing for Q1 2023, filed 3 May 2023.